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ABSTRACT
Background: Multi-drug resistance (MDR) remains a significant obstacle to 
successful chemotherapy treatment for osteosarcoma patients. One of the central 
causes of MDR is the overexpression of the membrane bound drug transporter 
protein P-glycoprotein (P-gp), which is the protein product of the MDR gene ABCB1. 
Though several methods have been reported to reverse MDR in vitro and in vivo when 
combined with anticancer drugs, they have yet to be proven useful in the clinical 
setting. 
Results: The meta-analysis demonstrated that a high level of P-gp may predict poor 
survival in patients with osteosarcoma. The expression of P-gp can be efficiently blocked 
by the clustered regularly interspaced short palindromic repeats (CRISPR)-associated 
Cas9 system (CRISPR-Cas9). Inhibition of ABCB1 was associated with reversing drug 
resistance in osteosarcoma MDR cell lines (KHOSR2 and U-2OSR2) to doxorubicin.
 Materials and Methods: We performed a meta-analysis to investigate the 
relationship between P-gp expression and survival in patients with osteosarcoma. 
Then we adopted the CRISPR-Cas9, a robust and highly efficient novel genome editing 
tool, to determine its effect on reversing drug resistance by targeting endogenous 
ABCB1 gene at the DNA level in osteosarcoma MDR cell lines. 
Conclusion: These results suggest that the CRISPR-Cas9 system is a useful tool 
for the modification of ABCB1 gene, and may be useful in extending the long-term 
efficacy of chemotherapy by overcoming P-gp-mediated MDR in the clinical setting.
INTRODUCTION
Osteosarcoma is one of the most common malignant 
tumors of bone, which mainly affects children and 
adolescents [1]. Current treatment for osteosarcoma 
involves surgical resection and multi-agent chemotherapy 
[1]. The advancement in intensive chemotherapy has 
significantly improved the 5-year survival rate from 
20% with surgery alone to approximately 60-70% when 
combined with chemotherapy [2]. However, systemic 
relapses still occur in 40% of patients, which are mostly 
linked to chemotherapy drug resistance [3]. Increasing 
drug dosage in histologically poor responders has not 
improved their outcome [4]. Nearly 50% of osteosarcoma 
cases are either resistant to chemotherapy or acquire 
resistance during treatment [5].
Overcoming drug resistance is one approach to 
improving the survival rate of osteosarcoma patients 
[6]. The development of drug resistance is associated 
with multiple mechanisms. One of the major causes of 
multi-drug resistance (MDR) is the overexpression of the 
membrane bound drug transporter protein P-glycoprotein 
(P-gp) [7, 8]. P-gp is the protein product of the MDR gene 
ABCB1 (ABC subfamily B member 1, also know as MDR-
1) and acts as an energy-dependent drug efflux pump 
that requires two ATPs to pump out many structurally 
unrelated chemotherapeutic drugs [8]. A direct correlation 
between P-gp expression levels and the degree of drug 
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resistance has been established in osteosarcoma cell 
lines [7, 9]. Several studies have tried to investigate the 
relevance of P-gp expression in osteosarcoma progression, 
but the results remain controversial [10-21]. For example, 
a previous study showed there was no correlation between 
MDR1 mRNA expression and disease progression in 
patients with osteosarcom [10]. However, another study 
found positive immuno-staining for P-gp is an independent 
risk factor for a poor outcome of osteosracoma patients 
[21]. In our previous study, we also found expression of 
P-gp is significantly predictor in patients with stage IIB 
osteosarcoma [17]. These data suggest that further study is 
required to clarify the prognostic value of P-gp expression 
in osteosarcoma. Meta-analysis uses a statistical approach 
that systematically combines the results from previous 
multiple research studies to obtain a conclusion [22].
Strategies for reversing and preventing MDR 
by targeting ABCB1 have been studied extensively in 
different MDR model systems, including in osteosarcoma, 
but have shown limited clinical potential [7-9]. A possible 
approach to circumvent MDR is the co-administration of 
inhibitors/compounds that inhibit the transport activity 
of MDR transporters [7, 9, 23]. Four generations of P-gp 
inhibitors have been developed [24], including verapamil, 
cyclosporine A (CsA), reserpine, dexverapamil, PSC-
883, VX710, XR9576 (tariquidar), R101933 (laniquidar), 
flavonoids, and a natural product, curcumin [25]. Other 
substances, such as a new synthetic rifampicin derivative, 
DiBenzRif, have recently been described to limit P-gp 
ATPase activity by enhancing membrane fluidity at sub-
toxic concentrations and consequently inhibiting the 
pump [26]. Our previous studies have demonstrated that 
the small molecular compound NSC23925 could reverse 
P-gp-mediated MDR in ovarian cancer by stimulating 
P-gp ATPase activity [27]. Furthermore, we evaluated the 
effects of NSC23925 on preventing the development of 
MDR in osteosarcoma and in ovarian cancer. Our studies 
noted that NSC23925 may prevent the development of 
MDR by specifically inhibiting the overexpression P-gp in 
both osteosarcoma and ovarian cancer [7, 28]. In addition, 
we confirmed that the small molecule inhibitors A-770041 
and NSC77037 may function to reverse P-gp-mediated 
chemotherapy drug resistance [23, 29]. Though these 
inhibitors have been reported to reverse MDR in vitro and 
in vivo when combined with anticancer drugs, they have 
yet to be proven useful in the clinical setting.
Recently, the CRISPR-Cas9 system, a novel genome 
editing tool, has been implemented in a multitude of model 
organisms and cell types [30]. The CRISPR-Cas9 system 
uses Cas9, which complexes with single guided RNA 
(sgRNA), to cleave DNA 3-4 base pairs upstream of a 
protospacer-adjacent motif (PAM) and generate double-
strand breaks (DSBs) in a sequence-specific manner [30]. 
The DSBs are then repaired either by non-homologous 
end joining (NHEJ)-mediated error-prone DNA repair 
or homologous directed repair (HDR)-mediated error-
free DNA repair [30]. The former repair can generate 
small insertion and deletion mutations at the target sites. 
These mutations can disrupt and abolish the function of 
target genes or genomic elements. HDR-mediated error-
free DNA repair requires a homology-containing donor 
DNA sequence as the repair template, which leads to 
precise gene correction or replacement [30]. It is evident 
that the CRISPR-Cas9 genome editing technology has 
revolutionized the field of genetic engineering and holds 
the potential to overcome many of the limitations of earlier 
techniques to carry out deletions, insertions, translocations, 
and inversions at specific sites in the DNA of cells [30].
Due to the controversial discussions on the 
relevance of P-gp expression in osteosarcoma, in this 
study, we first explore the correlation between P-gp 
expression and osteosarcoma prognosis through a meta-
analysis of published case-control studies. Then, we 
adopted the CRISPR-Cas9 system to specifically inhibit 
ABCB1 at the DNA level in osteosarcoma MDR cells, 
and further determined the effects of ABCB1 knockout 




A total of 707 studies were identified after 
searching in PubMed, Embase and Web of Science for 
publications on prognostic role of P-gp expression in 
osteosarcoma. The titles, publication types and abstracts 
were initially evaluated and the full texts were further 
reviewed. Finally, 11 studies that met the inclusion 
criteria were considered qualified for the present meta-
analysis. Figure 1 showed the flow diagram of candidate 
study selection in our study.
Characteristics of included studies
We collected the essential Data from the enrolled 11 
studies which were conducted between 1995 and 2016. A 
total of 723 participants from different territories involving 
the United States, Dermark, Italy, Korea, Japan and Canada. 
The sample size of the included study ranged from 19 to 
149 patients. Immunohistochemistry (IHC) was widely 
applied to detect the expression of P-gp. Included studies 
in this meta-analysis referred to evaluate P-gp expression 
for prognostic outcome in osteosarcoma. The main features 
of these 11 studies were summarized in Table 1.
Survival associated with P-gp expression in 
osteosarcoma
For studies evaluating survival outcome, a random 
effect model was applied to calculate the pooled risk ratios 
(RR) and its 95% confidence intervals (95% CIs) because 
of the significant heterogeneity had been found in the 11 
cohorts (I2 = 58.9%, P = 0.007). The result showed that 
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Figure 1: Flow diagram of the study selection process.
Table 1 Characteristics of the studies included in this meta-analysis
Author Publication year Origin of 
population
cases Test method Follow-up 
(years)
Gao Yan [11] 2016 United Sates 57 IHC 5
Sorensen [12] 2008 Denmark 116 IHC 5
Scotlandi [13] 2005 Italy 80 IHC 5
Ferrari [14] 2004 Italy 19 IHC 3
Serra [15] 2003 Italy 149 IHC 5
Park [16] 2001 Korea 35 IHC 5
Hornicek [17] 2000 United Sates 33 IHC 5
Yammamoto [18] 2000 Japan 28 IHC 5
Gorlick [19] 1999 United Sates 53 IHC 10
Chan [20] 1997 Canada 61 IHC 5
Baldini [21] 1995 Italy 92 IHC 5
IHC: Immunohistochemistry.
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high level of P-gp may predict poorer survival, with the 
pooled RR being 2.18 (95% CI: 1.61-2.95, P = 0.000) 
(Figure 2).
Publication bias
Potential publication bias was assessed by Begg’s 
funnel plot and Egger’s test [31, 32]. Among 11 cohorts 
evaluating survival outcome, no obvious asymmetry was 
observed in Begg’s funnel plots, and the Begg’s test results 
also showed no potential publication bias (P = 0.213 > 
0.05). The Egger’s test results also showed no potential 
publication bias (t =1.14, P =0.282>0.05).
Sensitivity analysis
Sensitivity analysis investigates the influence 
of each individual study on the overall meta-analysis 
estimate, which computes the pooled HRs by omitting 
one study in each turn. The results of sensitivity analysis 
show whether the studies are convincing and stable. In the 
leave-one-out sensitivity analyses for P-gp expression in 
osteosarcoma, it demonstrated that all data assessing the 
prognostic role of high P-gp expression in patients with 
osteosarcoma were stable as the endpoint.
Results of in vitro studies
Transfection of ABCB1 sgRNA-Cas9-GFP significantly 
inhibits P-gp expression
The CRISPR-Cas9 and green fluorescent protein 
(GFP) fusion protein expression vector U6gRNA-
Cas9+2A-GFP guide by ABCB1 sgRNA was abbreviated 
as ABCB1-Cas9-GFP (Figure 3). To determine the 
transfection efficiency of ABCB1-Cas9-GFP or pEGFP-N3 
plasmids into KHOSR2 and U-2OSR2 cells, fluorescence 
expression was evaluated by a fluorescence microscope. 
As illustrated in Figure 4A, GFP was detected in 
KHOSR2-pEGFP-N3, KHOSR2-ABCB1-Cas9-GFP, 
U-2OSR2-pEGFP-N3, and U-2OSR2-ABCB1-Cas9-GFP 
cells, which suggested that KHOSR2 and U-2OSR2 cells 
were successfully transfected with ABCB1-Cas9-GFP or 
pEGFP-N3.
CRISPR-Cas9 precisely enables specific genomic 
locus manipulation by providing sgRNA. To evaluate 
whether CRISPR-Cas9 complexed with ABCB1 sgRNA 
could inhibit P-gp expression, Western blotting was 
performed. The results demonstrated that P-gp protein 
Figure 2: P-gp expression and overall survival rate of osteosarcoma patients.
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expression was significantly inhibited in KHOSR2 cells 
transfected with ABCB1-Cas9-GFP. P-gp expression 
of KHOSR2 was repressed 11.34 ± 1.93 fold (p < 0.01) 
(Figure 4B & 4C). In the U-2OSR2 cells transfected with 
ABCB1-Cas9-GFP, P-gp expression was also significantly 
inhibited. P-gp expression of U-2OSR2 was repressed 5.80 
± 1.25 fold (p < 0.05) (Figure 4B & 4C). Furthermore, 
as expected, Cas9 protein was expressed in KHOSR2 
and U-2OSR2 cells transfected with ABCB1-Cas9-GFP 
(Figure 4B). These data revealed that P-gp expression 
was efficiently repressed in MDR osteosarcoma cell lines 
transfected with ABCB1-Cas9-GFP.
Knockout of ABCB1 by CRISPR-Cas9 restores MDR 
cell sensitivity to doxorubicin
After ABCB1 was knocked out by CRISPR-Cas9, 
we found that doxorubicin exhibited an increase in anti-
proliferative activity in KHOSR2-ABCB1-Cas9-GFP and 
U-2OSR2-ABCB1-Cas9-GFP cells in a dose-dependent 
manner, while cisplatin showed no significant difference 
in anti-proliferative activity in the ABCB1 knockout cells 
compared with that of the control cells (Figure 5). Notably, 
when the delivery of doxorubicin concentration was 1.0 
μM, growth inhibition was observed in KHOSR2 cells 
with or without transfection with pEGFP-N3, and when 
Figure 3: A. Schematic of U6 ABCB1 sgRNA-CMV Cas9-GFP expression cassette in the single plasmid system. GFP is co-expressed 
from the same mRNA as the Cas9 protein via a 2A peptide linkage, which enables tracking of transfection efficiency. The exon of ABCB1 
selected for guide RNA design is located on the fifth coding exon. The human U6 promoter is used to drive sgRNA expression, while the 
CMV promoter drives expression of Cas9 and GFP proteins. The position of the frame shift that CRISPR-Cas9 knocks out is located at the 
fifth exon within the ABCB1 gene (NM_000927.4 ABCB1). The red font is the 20 bp for sgRNA, and AGG (green font) is the sequence of 
PAM. B. Schematic structure of CRISPR-Cas9 system functions on targeting the ABCB1 gene. The core components of the CRISPR-Cas9 
system are a nuclease Cas9 and a single guided RNA (sgRNA). The CRISPR-Cas9 system uses Cas9, which complexes with sgRNA to 
cleave target DNA and generate double-strand breaks (DSBs) in a sequence-specific manner about 3-4 base pairs upstream of a protospacer 
adjacent motif (PAM). The red font is the 20 bp guide sequence for sgRNA, and AGG (green font) is the sequence of PAM. The black font 
in sgRNA sequence is the commonly used sequence for tracrRNA.
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the delivery of doxorubicin concentration was 0.3 μM, 
growth inhibition was detected in U-2OSR2 cells with or 
without transfection with pEGFP-N3. In the untransfected 
KHOSR2 cells and the KHOSR2 cells transfected with 
pEGFP-N3, the IC50 of doxorubicin was 1.71 μM and 
1.43 μM, respectively, which was reduced to 0.05 μM 
when the cells were transfected with ABCB1-Cas9-GFP. 
Likewise, the MDR cell line U-2OSR2 and U-2OSR2 
cells transfected with pEGFP-N3 displayed a similar 
trend-the IC50 of doxorubicin was 0.95 μM and 1.25 μM, 
respectively, which decreased to 0.02 μM when the cells 
were transfected with ABCB1-Cas9-GFP.
DISCUSSION
In the present meta-analysis, we show that high 
expression of P-gp could predict poor survival in 
patients with osteosarcoma. We further demonstrated 
that expression of P-gp can be efficiently blocked by 
the CRISPR-Cas9 system and inhibition of ABCB1 was 
associated with reversing drug resistance in osteosarcoma 
MDR cell lines (KHOSR2 and U-2OSR2) to doxorubicin. 
However, down regulation of P-gp had no effect on 
chemosensitivity to cisplatin in the ABCB1 knockout cells 
compared with the control cells.
Previously, we observed that MDR1 siRNA 
loaded dextran nanoparticles can efficiently suppressed 
P-gp expression in drug resistant osteosarcoma cell 
lines. However, RNAi based techniques can achieve 
only temporary and partial knockdown of transcribed 
mRNA, but not genomic DNA [9]. In this study, we 
adopted the CRISPR-Cas9 system to knockout ABCB1 
in osteosarcoma MDR cell lines. The position of ABCB1 
sgRNA target is located on the fifth exon of the ABCB1 
gene. CRISPR-Cas9 mediates cleavage of targets on DNA 
sites that are complementary to the 5’-20 nt region of the 
Figure 4: A. Fluorescence analysis showed that GFP was detected in KHOSR2- pEGFP-N3, KHOSR2-ABCB1-Cas9-GFP, U-2OSR2-
ABCB1-Cas9-GFP, and U-2OSR2-pEGFP-N3 cells, which suggests that KHOSR2 and U-2OSR2 cells were successfully transfected 
with ABCB1-Cas9-GFP or pEGFP. B. Western blotting analysis confirmed that P-gp protein expression was significantly inhibited in 
KHOSR2 and U-2OSR2 cells transfected with ABCB1-Cas9-GFP. Furthermore, Cas9 protein was expressed in KHOSR2 and U-2OSR2 
cells transfected with ABCB1-Cas9-GFP. C. P-gp expression was repressed 11.34 ± 1.93 fold (*p < 0.01) and 5.80 ± 1.25 fold (**p < 0.05) 
in KHOSR2 and U-2OSR2 cells transfected with ABCB1-Cas9-GFP, respectively.
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sgRNA that lies next to a PAM sequence. Compared to 
RNAi, the advantages of the CRISPR-Cas9 system include 
the fact that CRISPR-Cas9 is an exogenous system that 
does not compete with endogenous processes and that it 
functions at the DNA level to target transcripts, which 
results in knockdown or complete elimination of gene 
function [30]. Furthermore, the mechanism of CRISPR-
Cas9 that directly blocks transcription is distinct from 
that of RNAi, for which knockdown of gene expression 
requires the destruction of already transcribed mRNAs 
prior to their translation [33, 34]. In addition, CRISPR-
Cas9 could provide a larger targetable sequence space in 
which promoters of the gene may also be targeted [30]. 
Thus, CRISPR-Cas9 is a novel genome editing tool for 
switching gene expression at the DNA level [30].
CRISPR-Cas9 guided gene targeting is highly 
specific [33, 35]. To evaluate the specificity of CRISPR-
Cas9 on a genome-wide scale, scientists performed 
whole-transcriptome shotgun sequencing (RNA-seq) 
of Cas9-transformed cells with and without sgRNA co-
expression [33]. In the presence of the sgRNA targeted to 
red fluorescent protein (mRFP), the mRFP transcript was 
the sole gene that exhibited a decrease in abundance [33]. 
Furthermore, scientists also performed RNA-seq on cells 
with different sgRNAs that target different genes. None 
of these experiments showed significant changes in other 
genes besides the target gene [33]. In our study, the results 
showed that CRISPR-Cas9 guided by ABCB1 sgRNA 
markedly decreased P-gp expression in osteosarcoma 
MDR cell lines, whereas pEGFP-N3 had no effect on 
KHOSR2 or U-2OSR2 cell lines. Knockout of ABCB1 
by CRISPR-Cas9 restored the sensitivity of osteosarcoma 
MDR cell lines to doxorubicin, but not to cisplatin. These 
studies imply that sgRNA guided gene targeting and 
regulation is highly specific and ABCB1 sgRNA guided 
CRISPR-Cas9 can specifically knock out ABCB1.
Robust gene editing has been observed in both 
reporter genes and endogenous genes by CRISPR-
Cas9 system [36]. CRISPR-Cas9 is capable of inducing 
loss of function (LOF) and gain of function (GOF) 
mutations in vitro and in vivo. In our study, by delivering 
the combination of ABCB1 sgRNA and Cas9 with 
Lipofectamine® 3000 Reagent, P-gp protein expression 
was significantly silenced. There are several factors that 
affect repression efficiency. Firstly, the DNA carrier could 
influence the transfection efficiency and gene expression. 
In some studies, common lentiviral constructs were used 
to express both Cas9 and sgRNAs to achieve stable long 
term gene knockdown [36]. They observed 5- to 15-fold 
repression of both reporter genes and endogenous genes 
in human [36]. In our study, transfection of sgRNA-Cas9 
into KHOSR2 and U-2OSR2 cells was performed with 
Figure 5: After ABCB1 was knocked out by CRISPR-Cas9, doxorubicin exhibited an increase in anti-proliferative 
activity in MDR osteosarcoma cell lines in a dose-dependent manner A, B. while cisplatin showed no significant difference in 
anti-proliferative activity in the ABCB1 knockout cells compared with that of the control cells C, D. In the KHOSR2 cells alone, KHOSR2 
cells transfected with pEGFP-N3, and KHOSR2-ABCB1-Cas9-GFP cells, the IC50 of doxorubicin was 1.71 μM, 1.43 μM, and 0.05 μM, 
respectively. Likewise, the U-2OSR2 cells alone, U-2OSR2 transfected with pEGFP-N3, and U-2OSR2-ABCB1-Cas9-GFP cells, the IC50 
of doxorubicin was 0.95 μM, 1.25 μM, and 0.02 μM respectively.
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Lipofectamine® 3000 Reagent, and P-gp expression was 
repressed 5.80- to 11.34-fold. This is comparable to the 
efficiency of existing gene editing techniques, such as 
RNAi or transcription activator-like effector nucleases 
(TALENs) [30, 36]. Secondly, it is important for silencing 
efficiency that the location of the sgRNA target sequence 
be adjacent to the gene [33]. In a study, scientists noted 
that repression by CRISPR-Cas9 was inversely correlated 
with the target distance from the transcription start site 
[30]. The same results were shown by another group, and 
in their studies, efficient activation of endogenous genes 
could be achieved by three to five sgRNAs binding within 
a 300 bp region upstream of the transcription start site 
[35]. Using additional sgRNAs to target further upstream 
or downstream regions did not significantly improve the 
level of induction. Their data suggest that only a small 
number of sgRNAs targeting the proximal promoter is 
sufficient to activate endogenous genes [35]. In our study, 
we adopted sgRNA binding at the fifth exon of the ABCB1 
gene, which was able to knockout ABCB1 efficiently. 
Interestingly, while this manuscript was in the preparation, 
another group has used CRISPR-Cas9 to targeting ABCB1 
in canine kidney II cell line. This study also showed canine 
ABCB1 can be efficiently knocked out by CRISPR-Cas9 
[37].
In summary, we demonstrated that overexpression 
of P-gp could predict poor survival in patients with 
osteosarcoma. Our finding indicates that CRISPR-Cas9 
is a powerful gene editing technology that can knockout 
ABCB1 successfully. ABCB1 knockout could restore the 
sensitivity of osteosarcoma MDR cell lines to doxorubicin. 
These results suggest that the CRISPR-Cas9 system 
will be useful in extending the long-term efficacy of 




This meta-analysis was conducted in accordance 
with the standard guidelines of Preferred Reporting 
Items for Systematic Reviews and Meta-Analyses 
(PRISMA) 2009 Checklist (http://www.prismastatement.
org/statement.htm) and Meta-analysis of Observational 
Studies in Epidemiology group (MOOSE) [38].
Identification of relevant studies
Searching for relevant literatures was conducted up 
to March 20, 2016. Electronic sources included Pubmed 
(http://www.ncbi.nlm.nih.gov/pubmed), MEDLINE 
(http://medline.cos.com/) EMBASE (http://www.embase.
com/home) and Web of Science (http://wokinfo.com/) 
databases. The search strategy included the following 
sets of key words and their combination search terms: 
‘‘P-glycoprotein OR MDR1 OR ABCB1”, “osteosarcoma 
OR malignant bone tumor OR malignant bone cancer’’, 
and “survival OR prognosis OR outcome OR death”. We 
also performed a search for references of retrieved articles 
in order to identify other potentially eligible studies. The 
language was limited to English. Overlapping data from 
the same authors were excluded from our meta-analysis.
Two independent reviewers firstly searched 
potentially relevant studies by reading the titles and 
abstracts and then further checked by reading the full texts 
and assessed for inclusion. Other two senior reviewers 
double checked these extracted articles for a second time. 
Disagreements were resolved by discussion among these 
reviewers and consultation with another senior reviewer.
Eligibility criteria
Studies were considered eligible according to 
following criteria: (i) patients with osteosarcoma was 
studied; (ii) the associations between P-gp expression 
and survival outcome of patients were investigated; and 
(iii) sufficient data was provided to estimate RRs and 
corresponding 95%CIs.
Articles were excluded if they met the following 
criteria: (i) reviews, case reports, comments, conference 
abstracts, animal studies and laboratory studies; (ii) studies 
of non-dichotomous data; (iii) lack of crucial information 
to estimate RR and 95% CI.
Quality assessment
Two investigators critically assessed the quality of 
all the included studies based on the critical guidelines 
of the Dutch Cochrane Centre proposed by MOOSE 
for prognostic meta-analysis [38]. The key points of 
the review checklist included the following: (i) clear 
description of study population and origin of country, (ii) 
clear definition of diagnosis of osteosarcoma, (iii) clear 
explanation of study design, (iv) clear description of 
outcome assessment, (v) clear report of P-gp expression 
measure method, (vi) clear definition of cut-off of P-gp 
expression, and (vii) sufficient follow-up period. We 
excluded the studies without specifying any aspect 
concerning above so as not to compromise the quality of 
the meta-analysis.
Data extraction, conversion and analysis
General characteristics of the eligible articles in the 
meta-analysis were collected: name of the first author, 
year of publication, case number, origin of population, 
detection methods and prognosis outcome.
RRs with their 95% CIs were extracted according to 
the following methods [39]. Reported results for survival 
in included studies were considered eligible. In most 
instances, the total number of observed death cases and 
the number of samples in each group or the valuable data 
provided by the authors were extracted to calculate RRs. 
If only Kaplan–Meier curves are available, data were 
extracted from the graphical survival plots to estimate the 
RRs following the previously described method [39]. If 
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needed, we sought original data directly from the authors 
of the relevant studies. All the results extracted according 
to the above methods were compared, and disagreements 
were discussed among all the authors to resolve with 
consensus. The pooled RRs with their 95% CIs and P 
values were reported as the results, with an RR >1 being 
associated with elevated risk of mortality.
The association of P-gp expression with prognostic 
outcome in osteosarcoma was estimated by using RR and 
their associated 95% CI for each study. Heterogeneity 
of combined RRs was assessed by Cochran’s Q test and 
Higgin’s I2 statistic [40]. Heterogeneity was considered 
statistically significant as P<0.05 or I2 > 50%. A fixed 
effect model (Mantel-Haenszel test) was applied in the 
absence of between-study heterogeneity (P ≥ 0.05 or I2 ≤ 
50 %) [41], while the random effect model (Der Simonian 
and Laird method) was applied if significant heterogeneity 
was observed (P < 0.05 or I2 > 50 %) [42].
The Begg’s funnel plot and Egger’s bias indicator 
test were used to evaluate the potential publication bias 
among the included studies [38,39]. P<0.05 in all the 
two-sided statistical tests was regarded as significant. 
No corrections were made for multiple comparisons. All 
analyses were conducted using the STATA package version 
12.0 (Stata Corporation, College Station, Texas, USA).
In vitro studies
Human osteosarcoma MDR cell lines
The osteosarcoma MDR cell lines U-2OSR2 
(established by selection with doxorubicin) and KHOSR2 
(established by selection with doxorubicin) were previous 
reported by our laboratory [9, 29, 43, 44]. These cell lines 
with high level of P-gp were cultured in RPMI 1640 (Life 
Technologies, Grand Island, NY, USA) supplemented 
with 10% FBS, 100 units/mL penicillin, and 100μg/
mL streptomycin (Life Technologies, Grand Island, NY, 
USA). Cells were incubated at 37°C in 5% CO2-95% air 
atmosphere and passaged when near-confluent monolayers 
were achieved using trypsin-EDTA solution.
Drugs
Doxorubicin and cisplatin were provided by the 
pharmacy at the Massachusetts General Hospital Cancer 
Center. The stock solutions of doxorubicin were prepared 
according to the manufacturer’s specifications and stored 
at -20°C.
CRISPR-Cas9 plasmid design and purification
The CRISPR-Cas9 and green fluorescent protein 
(GFP) fusion protein expression vector U6gRNA-
Cas9+2A-GFP guide by ABCB1 sgRNA (abbreviated 
as ABCB1-Cas9-GFP) was purchased from Horizon 
Discovery (DNA 2.0 Inc., CA, USA). GFP was co-
expressed from the same mRNA as the Cas9 protein 
via a 2A peptide linkage, which enabled tracking of 
transfection efficiency. The exon of ABCB1 selected 
for sgRNA design is located on the fifth coding exon 
(Figure 3A). The ABCB1 sgRNA sequence is as follows: 
5’-CCAAACACCAGCATCATGAG-3’ (Figure 3B). 
The pEGFP-N3 plasmid was purchased from Clontech 
Laboratories, Inc. (Mountain View, CA, USA). Plasmids 
were purified using QIAGEN Plasmid Mega Kits 
(Hilden, Germany) according to the Plasmid Purification 
Handbook. To determine the yield of each plasmid, 
DNA concentrations were determined by both UV 
spectrophotometry at 260 nm and quantitative analysis on 
an agarose gel.
Work flow of Lipofectamine-mediated transfection of 
ABCB1 sgRNA-Cas9-GFP
Transfection of ABCB1 sgRNA-Cas9-GFP into 
KHOSR2 and U-2OSR2 cells was performed with 
Lipofectamine® 3000 Reagent (Life Technologies, 
Grand Island, NY, USA) according to the manufacturer’s 
instructions. Briefly, U-2OSR2 and KHOSR2 cells were 
seeded in 12-well plates at a density of 1.0×105 cells/
mL and 7×104 cells/mL, respectively, with 1 mL of 
cells per well. After 24 h, Opti-MEM® Medium was 
used to rinse the cells three times and 1 mL of serum-
free medium was added for cell culturing. Then, 1.5 μl 
of Lipofectamine® 3000 Reagent was diluted in 50 μl of 
Opti-MEM® Medium, and a master mix of 1 μg DNA in 
50 μl of Opti-MEM® Medium was prepared with 2.0 μl 
P3000™ Reagent. Next, the diluted DNA was added to the 
tube of diluted Lipofectamine® 3000 Reagent (1:1 ratio). 
After incubation for 5 min at room temperature, the DNA-
lipid complex was added to the cells. After incubation 
for 48 h, the positive cells successfully transfected with 
ABCB1 sgRNA-Cas9-GFP plasmid were sorted by flow 
cytometry and the cultures were expanded for further 
study; untransfected cells were used as controls.
Fluorescence microscope observation
To observe the transfection efficiency of ABCB1-
Cas9-GFP or pEGFP-N3 plasmid expression into the 
U-2OSR2 and KHOSR2 cells, fluorescence analysis used 
to determine the GFP expression levels in the transfected 
cells. Briefly, U-2OSR2 and KHOSR2 cells were seeded 
in 12-well plates at a density of 1.0×105 cells/ml and 
7×104 cells/ml, respectively, with 1 mL of cells per well. 
The cells were then transfected with ABCB1-Cas9-GFP 
or pEGFP-N3 plasmid. After incubation for 48 h, the 
cells were evaluated under fluorescence. Osteosarcoma 
MDR cells were then visualized on a Nikon Eclipse Ti-U 
fluorescence microscope (Nikon Instruments, Inc., NY) 
equipped with a SPOTRT digital camera from Diagnostic 
Instruments, Inc. (Sterling Heights, MI).
Western blotting
After transfection of the ABCB1-Cas9-GFP plasmid, 
expression of the P-gp protein in KHOSR2 and U-2OSR2 
cells was evaluated by Western blotting. Protein lysates 
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from osteosarcoma cells were extracted using 1× RIPA 
Lysis Buffer (Upstate Biotechnology, Charlottesville, VA, 
USA). The protein concentrations were determined by 
Protein Assay Reagents (Bio-Rad, Hercules, CA, USA) 
and a SPECTRAmax Microplate Spectrophotometer from 
Molecular Devices (Sunnyvale, CA, USA). The primary 
monoclonal antibodies for ABCB1 (1:1000 dilution) 
and Cas9 (1:1000 dilution) were purchased from Cell 
Signaling Technology (Danvers, MA, USA). Secondary 
antibodies IRDye®800CW or IRDye®680LT were 
purchased from LI-COR Biosciences (Lincoln, NE, USA). 
Western blotting analyses were carried out as previously 
described12. Membrane signals were scanned using the 
Odyssey infrared imaging system and analyzed using 
Odyssey 3.0 software (LI-COR Biosciences, NE, USA). 
Relative expression values were normalized assigning the 
value of the cells in control groups to 1.0.
MTT assay
The MTT assay was performed to estimate the 
drug resistance profile of the tested cells to doxorubicin 
and cisplatin. Briefly, KHOSR2 or U-2OSR2 cells 
transfected with or without pEGFP-N3 or ABCB1-Cas9-
GFP were seeded into 96-well culture plates at a density 
of 3×103 cells per well. The cells were then treated with 
increasing concentrations of doxorubicin or cisplatin 
for five days. Afterwards, 20 µL of MTT (5 mg/mL in 
PBS, purchased from Sigma-Aldrich, MO, USA) was 
added to each well and the plates were incubated for an 
additional four hours. Finally, the resulting formazan 
product was dissolved with acid (HCl)-isopropanol and 
the absorbance at a wavelength of 490nm was read on 
a SPECTRAmax Microplate Spectrophotometer from 
Molecular Devices (Sunnyvale, CA, USA). Experiments 
were done in triplicate. Dose-response curves were fitted 
using GraphPad PRISM 5 software (GraphPad Software, 
La Jolla, CA).
Statistical analysis
GraphPad PRISM 5 software (GraphPad Software, 
La Jolla, CA) was used to statistically analyze the data. 
The differences between groups were also evaluated using 
the two-sided Student’s t-test. Errors were SD of averaged 
results, p values <0.05 were considered statistically 
significant between means, and p values <0.01 were 
accepted as a significant difference between means.
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